Arixa Tablet

Arixa is a highly potent, selective, and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that improves glycemic control in patients with type 2 diabetes mellitus by reducing renal glucose reabsorption leading to urinary excretion of excess glucose (glucuresis).


Arixa is used for an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Arixa is also used to associated treatment for these conditions: Type 2 Diabetes Mellitus

Trade Name Arixa
Generic Dapagliflozin
Other Names Dapagliflozin, Dapagliflozina
Weight 5mg
Type Tablet
Formula C21H25ClO6
Weight Average: 408.873
Monoisotopic: 408.133966239
Protein binding


Therapeutic Class Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Manufacturer Ziska Pharmaceuticals Ltd
Available Country Bangladesh
Last Updated: June 23, 2021 at 11:19 am


Arixa dosage

5 mg orally once a day. May increase to 10 mg orally once a day in patients tolerating therapy with 5 mg and requiring additional glycemic control

Side Effects

Renal impairment, Female genital mycotic infections, Urinary tract infection, Increased urination, Male genital mycotic infections, Dyslipidemia, Constipation, Discomfort with urination, Extremity pain, Volume depletion, Hypersensitivity


CV disease, history of hypotension, UTI, Children, Elderly. Unknown whether distributed in human breast milk; breastfeeding women should discontinue dapagliflozin or nursing taking into account the importance of the drug to the mother


Hypoglycemia may occur with concomitant use with insulin & insulin secretagogues eg sulfonylureas. Decrease in Cmax & AUC with rifampin. Increase in Cmax & AUC with mefenamic acid. Increased thiazide & loop diuretic effects; may increase risk of dehydration & hypotension. Pioglitazone.

Food Interaction

  • Avoid excessive or chronic alcohol consumption. Binge drinking or drinking alcohol often may predispose patients to ketoacidosis.
  • Take with or without food.

Volume of Distribution


Half Life



Oral plasma clearance was 4.9 mL/min/kg, and renal clearance was 5.6 mL/min.

Pregnancy & Breastfeeding use

Pregnancy Category-C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks


Hypersensitivity to dapagliflozin propanediol or to any of the excipients. Moderate to severe renal impairment; end-stage renal disease; active bladder cancer. Pregnancy (2nd & 3rd trimester) & lactation.

Special Warning

Renal Impairment: No dosage adjustment is indicated based on renal function. The efficacy is dependent on renal function. lt is not recommended for use in patients with moderate to severe renal impairment (patients with CrCI <60 mL/min or eGFR <60 mL/min/1.73 m2).

Arixa contains Dapagliflozin see full prescribing information from innovator Monograph